Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY43.44 CNY
Change Today -0.18 / -0.41%
Volume 6.7M
600276 On Other Exchanges
As of 1:02 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

jiangsu hengrui medicine c-a (600276) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/15 - CNY52.37
52 Week Low
08/28/14 - CNY25.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JIANGSU HENGRUI MEDICINE C-A (600276)

Related News

No related news articles were found.

jiangsu hengrui medicine c-a (600276) Related Businessweek News

No Related Businessweek News Found

jiangsu hengrui medicine c-a (600276) Details

Jiangsu Hengrui Medicine Co., Ltd. researches, manufactures, and sells pharmaceutical products in China. It offers antineoplastic, angiomyocardiac, antibiotic, and other drugs, as well as APIs in the form of tablets, injectables, injections, oral solutions, capsules, and ointments. The company was founded in 1970 and is headquartered in Lianyungang, China.

Founded in 1970

jiangsu hengrui medicine c-a (600276) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jiangsu hengrui medicine c-a (600276) Key Developments

Jiangsu Hengrui Medicine Co., Ltd. Announces Earnings Results for the First Half of 2015

Jiangsu Hengrui Medicine Co., Ltd. announced earnings results for the first half of 2015. For the period, the company reported basic earnings per share of CNY 0.5424 and weighted average return on net assets of 12.52%.

Jiangsu Hengrui Medicine Co., Ltd., Board Meeting, Aug 24, 2015

Jiangsu Hengrui Medicine Co., Ltd., Board Meeting, Aug 24, 2015. Agenda: To discuss and approve the full text of semi-annual report of 2015 and its abstract; and to approve the proposal of nominating Cao Guoqing Deputy General Manager.

Jiangsu Hengrui Medicine Co., Ltd. Reaches an Agreement with the US Tesaroe to Introduce the Latter's Patent Anti-Emetic Drug for Tumor Adjuvant Therapy, Rolapitant

Jiangsu Hengrui Medicine Co., Ltd. reached an agreement with the US Tesaroe to introduce the latter's patent anti-emetic drug for tumor adjuvant therapy, Rolapitant, and be responsible for the clinical research and development, registration and marketing of the drug in China. Rolapitant, researched and developed by Tesaro, is an NK-1 receptor antagonist and has two forms. The oral dosage form has completed the phase III clinical trial in the US and is pending for approval from the FDA to come to market. The injection form is conducting the phase I clinical trial in the US.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600276:CH CNY43.44 CNY -0.18

600276 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600276.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600276 Industry Range
Price/Earnings 49.3x
Price/Sales 10.4x
Price/Book 9.7x
Price/Cash Flow 49.4x
TEV/Sales 9.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JIANGSU HENGRUI MEDICINE C-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at